This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Steris (STE) Q3 Dismal: Earnings Miss Estimates, View Cut
by Zacks Equity Research
Steris Plc (STE) reported third-quarter fiscal 2017 adjusted earnings per share (EPS) of 98 cents, in line with the year-ago quarter.
Haemonetics (HAE) Beats Q3 Earnings & Revenue Estimates
by Zacks Equity Research
Haemonetics Corporation (HAE) reported adjusted earnings per share (EPS) of 43 cents in the third quarter of fiscal 2017, beating the Zacks Consensus Estimate by 7.5%.
Cardinal Health (CAH) Q2 Earnings Beat Estimates, Rise Y/Y
by Zacks Equity Research
Cardinal Health Inc. (CAH) reported second-quarter fiscal 2017 adjusted earnings of $1.34 per share, which beat the Zacks Consensus Estimate of $1.24 and increased 3% on a year-over-year basis.
Luminex (LMNX) Posts Loss in Q4, Revenues Miss Estimates
by Zacks Equity Research
Luminex Corporation (LMNX) reported loss of 8 cents per share in the fourth quarter of 2016, comparing unfavorably with the Zacks Consensus Estimate of adjusted earnings of 4 cents per share.
Phirbo Animal (PAHC) Tops Q2 Earnings, Reaffirms FY17 View
by Zacks Equity Research
Phibro Animal Health Corporation (PAHC) reported adjusted earnings per share (EPS) of 39 cents in the second quarter of fiscal 2017.
SurModics (SRDX) Beats Earnings & Revenue Estimates in Q1
by Zacks Equity Research
Surmodics, Inc. (SRDX) reported earnings of 19 cents per share in the first-quarter of fiscal 2017 surpassing the Zacks Consensus Estimate of 9 cents.
Pacific Biosciences (PACB) Q4 Loss Narrower than Estimated
by Zacks Equity Research
Pacific Biosciences of California Inc. (PACB), a pioneer in the field of single molecule long resequencing, reported loss of 21 cents per share in the fourth quarter of 2016, 2 cents narrower than the Zacks Consensus Estimate.
QIAGEN (QGEN) Earnings Meet, Sales Miss Estimates in Q4
by Zacks Equity Research
QIAGEN N.V. (QGEN) reported fourth-quarter 2016 adjusted earnings per share (excluding restructuring expenses) of 39 cents, up 7.7% year over year.
IDEXX Laboratories (IDXX) Q4 Earnings Rise; Tweaks View
by Zacks Equity Research
IDEXX Laboratories Inc. (IDXX) recorded fourth-quarter 2016 earnings per share (EPS) of 58 cents, up 21% year over year on a reported basis.
Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2017 earnings of $2.33 per share, which beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter.
Boston Scientific (BSX) Tops Q4 Earnings, Offers 2017 View
by Zacks Equity Research
Boston Scientific Corporation (BSX) posted adjusted earnings per share (EPS) of 30 cents, up 15.4% from the year-ago adjusted number.
Hologic (HOLX) Beats on Q1 Earnings, Lowers '17 Guidance
by Zacks Equity Research
Hologic Inc. (HOLX) reported first-quarter fiscal 2017 adjusted earnings per share (EPS) of 52 cents, up 13% year over year.
Zacks.com featured highlights: DNB Financial, NVE, Nova Measuring Instruments, Glaukos and County Bancorp
by Zacks Equity Research
Zacks.com featured highlights: DNB Financial, NVE, Nova Measuring Instruments, Glaukos and County Bancorp
Edwards Lifesciences (EW) Beats on Earnings & Sales in Q4
by Zacks Equity Research
Edwards Lifesciences Corp. (EW) reported fourth-quarter 2016 adjusted earnings per share (EPS) of 75 cents, which surpassed the Zacks Consensus Estimate by 5.6%.
CONMED (CNMD) Q4 Earnings Miss Estimates, Increase Y/Y
by Zacks Equity Research
Headquartered in Utica, NY, leading medical technology player, CONMED Corporation (CNMD) reported fourth-quarter 2016 adjusted earnings of 54 cents per share, missing the Zacks Consensus Estimate by 2 cents.
Baxter International (BAX) Q4 Earnings Beat, Revenues Lag
by Zacks Equity Research
Baxter International Inc. (BAX) reported fourth-quarter 2016 adjusted earnings of 57 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and were well above the year-ago figure of 43 cents.
Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue
by Zacks Equity Research
Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Align Technology (ALGN) Q4 Earnings and Revenues in Line
by Zacks Equity Research
Align Technology Inc. (ALGN) reported adjusted earnings of 67 cents per share in the fourth quarter of 2016, up 11.6% from 60 cents in the year-ago quarter.
Illumina (ILMN) Beats Q4 Earnings & Revenues, Guides 2017
by Zacks Equity Research
Illumina Inc. (ILMN) reported adjusted earnings per share (EPS) of 85 cents in the fourth quarter of 2016, which exceeded the Zacks Consensus Estimate by 4.9%.
Zimmer Biomet (ZBH) Beats on Q4 Earnings, Knees Improve
by Zacks Equity Research
Zimmer Biomet Holdings, Inc. (ZBH) reported fourth-quarter 2016 adjusted earnings per share (EPS) of $2.14, up 2.4% year over year.
Hill-Rom TruSystem 3000 Table Boosts Surgical Solution Suite
by Zacks Equity Research
Hill-Rom Holdings (HRC) recently launched TruSystem 3000 Mobile Operating Table to fulfill hospitals' need to equip operating rooms with quality medical devices at a reasonable cost.
Thermo Fisher (TMO) Q4 Earnings Beat, Organic Sales Flat
by Zacks Equity Research
Thermo Fisher Scientific, Inc. (TMO) reported better-than-expected fourth-quarter and full-year 2016 earnings results.
Abiomed (ABMD) Beats Earnings & Revenue Estimates in Q3
by Zacks Equity Research
Abiomed Inc. (ABMD) reported third-quarter fiscal 2017 earnings of 34 cents per share, which surpassed the Zacks Consensus Estimate by 5 cents and surged 47.8% from the year-ago quarter.
C.R. Bard (BCR) Q4 Earnings & Sales Better Than Expected
by Zacks Equity Research
C.R. Bard Inc. (BCR) reported adjusted earnings of $2.77 in the fourth quarter of 2016, exceeding the Zacks Consensus Estimate by 4 cents and improving from the year-ago quarterly number of $2.43.
Quality Systems (QSII) Beats on Earnings & Revenues in Q3
by Zacks Equity Research
Irvine, CA-based Quality Systems Inc. (QSII) reported third-quarter fiscal 2017 adjusted earnings of 21 cents per share, exceeding the Zacks Consensus Estimate of 18 cents.